• linkedin
  • Increase Font
  • Sharebar

    Targeted treatments for atopic dermatitis

    Novel immunomodulators expected to usher in new therapeutic era


    Topical treatments

    Considering that local therapy has a role in all patients with AD and, with the limitations of existing options, there is also a huge unmet need for new topical agents

    “There is a lot of public phobia about topical corticosteroids, and the topical calcineurin inhibitors carry a black box warning,” Dr. Guttman-Yassky says.

    The topical PDE-4 inhibitor crisaborole 2% ointment (Pfizer) showed promising results in trials and was approved for mild-to-moderate atopic dermatitis by the U.S. Food and Drug Administration in December, 2016. The approval was based on the positive results from the phase 3 trials. Crisaborole is approved for children and adults 2 years of age and older.

    In a phase 2a vehicle-controlled trial, the topical JAK inhibitor tofacitinib (Pfizer) showed great results when used to treat adults with mild-to-moderate AD.

    “In fact, the benefit of topical tofacitinib was much better for AD than for psoriasis,” Dr. Guttman-Yassky says.

    “Most ongoing studies with JAK inhibitors involve systemic agents, but hopefully other topical JAK inhibitors will follow the promising study with topical tofacitinib because there is a great need for new topical treatments.”

    Disclosures: Dr. Guttman-Yassky is a consultant to most companies that develop medications for AD, including the agents mentioned in this article, but she receives no financial gain from any product.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow